GlassScriptPhysician profile
Daniel J Moulton
NPI 1447201801
$1,404.02
in general payments reported to CMS, 2019-2025
20 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $270 · 2022: $94.75 · 2023: $178 · 2024: $306 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $436.21 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $236.10 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $132.83 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $115.89 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $82.97 | 2019-2023 | Doc Band |
| Sanofi Pasteur INC. | $60.91 | 2022-2025 | |
| Neos Therapeutics, LP | $57.76 | 2019-2022 | |
| Pfizer INC. | $56.82 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $32.78 | 2019-2023 | Rotateq, Vaxneuvance, Gardasil 9 |
| Seqirus USA INC | $22.99 | 2024 | Flucelvax |
| Adlon Therapeutics L.P. | $21.26 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.00 | 2019 | |
| Tris Pharma INC | $18.85 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.23 | 2025 | Relexxii |
| Ultragenyx Pharmaceutical INC. | $17.27 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.86 | 2025 | |
| Medimetriks Pharmaceuticals, INC. | $15.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.12 | 2025 | Zoryve |
| Arbor Pharmaceuticals, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Moulton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.